A detailed history of Davenport & CO LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Davenport & CO LLC holds 171,254 shares of ABBV stock, worth $34.9 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
171,254
Previous 171,833 0.34%
Holding current value
$34.9 Million
Previous $29.5 Million 14.75%
% of portfolio
0.2%
Previous 0.18%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$163.84 - $199.33 $94,863 - $115,412
-579 Reduced 0.34%
171,254 $33.8 Million
Q2 2024

Aug 06, 2024

BUY
$154.79 - $180.76 $84,979 - $99,237
549 Added 0.32%
171,833 $29.5 Million
Q1 2024

May 03, 2024

SELL
$159.82 - $182.1 $2.21 Million - $2.51 Million
-13,798 Reduced 7.46%
171,284 $31.2 Million
Q4 2023

Jan 23, 2024

BUY
$137.6 - $154.97 $384,454 - $432,986
2,794 Added 1.53%
185,082 $28.7 Million
Q3 2023

Oct 17, 2023

SELL
$133.59 - $154.65 $1.05 Million - $1.21 Million
-7,851 Reduced 4.13%
182,288 $27.2 Million
Q2 2023

Jul 20, 2023

SELL
$132.51 - $164.9 $371,558 - $462,379
-2,804 Reduced 1.45%
190,139 $25.6 Million
Q1 2023

Apr 27, 2023

SELL
$144.61 - $166.54 $1.26 Million - $1.45 Million
-8,701 Reduced 4.32%
192,943 $30.7 Million
Q4 2022

Jan 20, 2023

BUY
$138.31 - $165.87 $518,939 - $622,344
3,752 Added 1.9%
201,644 $0
Q3 2022

Oct 11, 2022

BUY
$134.21 - $153.93 $62,944 - $72,193
469 Added 0.24%
197,892 $26.6 Million
Q2 2022

Jul 18, 2022

SELL
$137.62 - $174.96 $647,226 - $822,836
-4,703 Reduced 2.33%
197,423 $30.2 Million
Q1 2022

May 02, 2022

BUY
$131.98 - $163.75 $375,351 - $465,705
2,844 Added 1.43%
202,126 $32.8 Million
Q4 2021

Feb 10, 2022

BUY
$107.43 - $135.93 $2.32 Million - $2.93 Million
21,588 Added 12.15%
199,282 $27 Million
Q3 2021

Oct 14, 2021

BUY
$106.4 - $120.78 $4.52 Million - $5.13 Million
42,478 Added 31.41%
177,694 $19.2 Million
Q2 2021

Jul 28, 2021

BUY
$105.21 - $117.21 $2.37 Million - $2.64 Million
22,528 Added 19.99%
135,216 $15.2 Million
Q1 2021

Apr 28, 2021

BUY
$102.3 - $112.62 $931,850 - $1.03 Million
9,109 Added 8.79%
112,688 $12.2 Million
Q4 2020

Jan 13, 2021

BUY
$80.49 - $108.67 $132,888 - $179,414
1,651 Added 1.62%
103,579 $11.1 Million
Q3 2020

Oct 15, 2020

SELL
$85.91 - $100.83 $267,695 - $314,186
-3,116 Reduced 2.97%
101,928 $8.93 Million
Q2 2020

Jul 28, 2020

BUY
$73.37 - $98.18 $876,184 - $1.17 Million
11,942 Added 12.83%
105,044 $10.3 Million
Q1 2020

May 05, 2020

BUY
$64.5 - $97.79 $942,603 - $1.43 Million
14,614 Added 18.62%
93,102 $7.09 Million
Q4 2019

Jan 22, 2020

SELL
$72.13 - $90.25 $44,432 - $55,594
-616 Reduced 0.78%
78,488 $6.95 Million
Q3 2019

Oct 16, 2019

BUY
$62.98 - $75.72 $11,840 - $14,235
188 Added 0.24%
79,104 $5.75 Million
Q2 2019

Jul 10, 2019

SELL
$65.7 - $83.98 $129,297 - $165,272
-1,968 Reduced 2.43%
78,916 $5.74 Million
Q1 2019

Apr 17, 2019

SELL
$77.14 - $90.79 $663,404 - $780,794
-8,600 Reduced 9.61%
80,884 $6.52 Million
Q4 2018

Jan 28, 2019

SELL
$77.85 - $96.01 $286,955 - $353,892
-3,686 Reduced 3.96%
89,484 $8.25 Million
Q3 2018

Oct 11, 2018

SELL
$88.91 - $98.84 $751,378 - $835,296
-8,451 Reduced 8.32%
93,170 $8.81 Million
Q2 2018

Jul 09, 2018

BUY
$89.78 - $106.23 $160,436 - $189,833
1,787 Added 1.79%
101,621 $9.42 Million
Q1 2018

Apr 04, 2018

SELL
$92.01 - $123.21 $3.07 Million - $4.12 Million
-33,403 Reduced 25.07%
99,834 $9.45 Billion
Q4 2017

Jan 17, 2018

SELL
$89.56 - $98.21 $214,227 - $234,918
-2,392 Reduced 1.76%
133,237 $12.9 Billion
Q3 2017

Oct 12, 2017

BUY
$69.85 - $89.22 $9.47 Million - $12.1 Million
135,629
135,629 $12.1 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $360B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Davenport & CO LLC Portfolio

Follow Davenport & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.